Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, Cobble ME, McCullough PA.
Kluger AY, et al. Among authors: cobble me.
Cardiovasc Diabetol. 2019 Aug 5;18(1):99. doi: 10.1186/s12933-019-0903-4.
Cardiovasc Diabetol. 2019.
PMID: 31382965
Free PMC article.
Review.